Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 14/20 | 0.55 |
| ▸ | DPP7 | Q9UHL4 | 12/20 | 0.55 |
| ▸ | DPP8 | Q6V1X1 | 7/20 | 0.55 |
| ▸ | DPP9 | Q86TI2 | 5/20 | 0.55 |
| ▸ | CCR6 | P51684 | 1/20 | 0.41 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | LDHB | P07195 | 1/20 | 0.39 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.39 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.39 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL3339763 | 1.00 | DPP4 (0.55) | DPP4DPP7DPP8DPP9CCR6 | |
| SCHEMBL12651058 | 0.93 | DPP4 (0.49) | DPP4DPP7DPP8DPP9CCR6 | |
| SCHEMBL12651463 | 0.93 | DPP4 (0.49) | DPP4DPP7DPP8DPP9CCR6 | |
| Trifluoroacetic Acid SCHEMBL3338278 | 0.82 | OPRM1 (0.50) | DPP4DPP7DPP8DPP9CCR6 | |
| Trifluoroacetic Acid SCHEMBL3341720 | 0.80 | DPP4 (0.44) | DPP4DPP7DPP8DPP9CCR6 | |
| Trifluoroacetic Acid SCHEMBL3339283 | 0.79 | DPP4 (0.43) | DPP4DPP7DPP8DPP9CCR6 | |
| Trifluoroacetic Acid SCHEMBL3340025 | 0.78 | OPRM1 (0.47) | DPP4DPP7DPP8DPP9CCR6 | |
| Trifluoroacetic Acid SCHEMBL16194723 | 0.78 | DPP4 (0.42) | DPP4DPP7DPP8DPP9CCR6 | |
| Trifluoroacetic Acid SCHEMBL3339667 | 0.77 | DPP4 (0.42) | DPP4DPP7DPP8DPP9CCR6 | |
| Trifluoroacetic Acid SCHEMBL3340014 | 0.77 | CTSC (0.44) | DPP4DPP7DPP8DPP9CCR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140323487-A1 | Novel Compounds As Antagonists Or Inverse Agonists At Opioid Receptors | GLAXOSMITHKLINE LLC | 2014-10-30 | — | — | US | disclosed |
| US-20100113512-A1 | METHOD OF TREATMENT USING NOVEL ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS | IGNAR DIANE MICHELE | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113512-A1 | METHOD OF TREATMENT USING NOVEL ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS | OPRL1, OPRD1, OPRK1 | DPP4 1431/4885DPP7 1333/4885DPP8 2313/4885 |
| US-20140323487-A1 | Novel Compounds As Antagonists Or Inverse Agonists At Opioid Receptors | OPRL1, OPRM1, OPRK1 | DPP4 1228/4885DPP7 1096/4885DPP8 932/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.